Antidepressant's long-term effect on cognitive performance and cardiovascular system

Автор: Nasser A.H.S.

Статья в выпуске: 23, 2022 года.

Бесплатный доступ

Background: The nature of antidepressants and their adverse effects should be considered when treating severe depression in individuals with psychotic symptoms. Antidepressant prescription rates have risen steadily over the last 30 years, affecting people of all ages. Aim: The goal of this study was to see if depression and antidepressant usage were linked to long-term changes in cognitive function and cardiovascular health. Methodology: Meta-analysis was performed using PRISMA guidelines along with using the SPIDER search framework using related keywords on different search engines i.e. Google scholars, PubMed, Scopus, ISI, etc. Total (n=2256) papers were obtained and assessed for eligibility. Altogether 15 studies were included using databases and other methods. The Newcastle-Ottawa Scale examined the grades provided by the data after numerous screenings. Result: A distinct link was found between antidepressants with cognitive performance and the cardiovascular system. Dementia and hypertension were prevailing long-term effects caused by frequent use of antidepressants in chronic and mild depression.

Еще

Depression, depressive disorder, antidepressants, long-term effect, cognition, cognitive performance, cardiovascular system

Короткий адрес: https://sciup.org/148326572

IDR: 148326572 | DOI: 10.18137/cardiometry.2022.23.7688

Список литературы Antidepressant's long-term effect on cognitive performance and cardiovascular system

WHO, Other common mental disorders: global health estimates. Geneva: World Health Organization, 2017. 24.
Friedrich, M.J., Depression is the leading cause of disability around the world. Jama, 2017. 317(15): p. 1517-1517.
El-Hage, W., et al., Mechanisms of antidepressant resistance. Front Pharmacol. 2013; 4: 146. 2013.
Hillhouse, T.M. and J.H. Porter, A brief history of the development of antidepressant drugs: from monoamines to glutamate. Experimental and clinical psychopharmacology, 2015. 23(1): p. 1.
Depression Rates by Country 2022. 2022 World Population by Country.
Roth, G., Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2018. The Lancet, 2018. 392: p. 1736-1788.
Schneider, L., Pharmacologic considerations in the treatment of late life depression. American Journal of Geriatric Psychiatry, 1996. 4(4): p. S51-S65.
Thapa, P.B., et al., Antidepressants and the risk of falls among nursing home residents. New England Journal of Medicine, 1998. 339(13): p. 875-882.
Pilevarzadeh, M., et al., Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis. Breast cancer research and treatment, 2019. 176(3): p. 519-533.
Hare, D.L., et al., Depression and cardiovascular disease: a clinical review. European heart journal, 2014. 35(21): p. 1365-1372.
Caeiro, L., et al., Depression in acute stroke. Journal of psychiatry and neuroscience, 2006. 31(6): p. 377-383.
Ansari, F., et al., The effects of probiotics and prebiotics on mental disorders: a review on depression, anxiety, Alzheimer, and autism spectrum disorders. Current pharmaceutical biotechnology, 2020. 21(7): p. 555-565.
Laux, G., Parkinson and depression: review and outlook. Journal of Neural Transmission, 2022: p. 1-8.
Norman, T.R., Antidepressant Treatment of Depression in the Elderly: Efficacy and Safety Considerations. OBM Neurobiology, 2021. 5(4): p. 1-1.
Lockhart, P. and B. Guthrie, Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. British Journal of General Practice, 2011. 61(590): p. e565-e572.
Abeyta, M.J., et al., Unique gene expression signatures of independently-derived human embryonic stem cell lines. Human molecular genetics, 2004. 13(6): p. 601-608.
Patten, S.B. and C.A. Beck, Major depression and mental health care utilization in Canada: 1994 to 2000. The Canadian Journal of Psychiatry, 2004. 49(5): p. 303-309.
Schmidt, H.D. and R.S. Duman, The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behavioural pharmacology, 2007. 18(5-6): p. 391-418.
Malberg, J.E., et al., Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. Journal of Neuroscience, 2000. 20(24): p. 9104-9110.
Dixon, O. and G. Mead, Selective serotonin reuptake inhibitors for mild cognitive impairment: a systematic review. J Neurol Disord Stroke, 2013. 1(3): p. 1022.
Hanlon, J.T., S.M. Handler, and N.G. Castle, Antidepressant prescribing in US nursing homes between 1996 and 2006 and its relationship to staffing patterns and use of other psychotropic medications. Journal of the American Medical Directors Association, 2010. 11(5): p. 320-324.
Freedland, K.E., et al., Cognitive behavior therapy for depression and self-care in heart failure patients: a randomized clinical trial. JAMA internal medicine, 2015. 175(11): p. 1773-1782.
Oh, S.W., et al., Antidepressant use and risk of coronary heart disease: meta‐analysis of observational studies. British Journal of Clinical Pharmacology, 2014. 78(4): p. 727-737.
Coupland, C., et al., Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. bmj, 2016. 352.
Watts, F.N., et al., Memory deficit in clinical depression: processing resources and the structure of materials. Psychological Medicine, 1990. 20(2): p. 345-349.
Weingartner, H., et al., Cognitive processes in depression. Archives of General Psychiatry, 1981. 38(1): p. 42-47.
Byrne, D., Affect and vigilance performance in depressive illness. Journal of Psychiatric Research, 1977. 13(3): p. 185-191.
Judd, L.L., et al., Effects of psychotropic drugs on cognition and memory in normal humans and animals, in Psychopharmacology: The third generation of progress. 1987, Raven Press.
Lesman-Leegte, I., et al., Depressive symptoms and outcomes in patients with heart failure: data from the COACH study. European journal of heart failure, 2009. 11(12): p. 1202-1207.
Frasure-Smith, N., et al., Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. Circulation, 2009. 120(2): p. 134-140.
Albert, N.M., et al., Depression and clinical outcomes in heart failure: an OPTIMIZE-HF analysis. The American journal of medicine, 2009. 122(4): p. 366-373.
Sherwood, A., et al., Relationship of depression to death or hospitalization in patients with heart failure. Archives of internal medicine, 2007. 167(4): p. 367-373.
Jiang, W., et al., Relationship between depressive symptoms and long-term mortality in patients with heart failure. American heart journal, 2007. 154(1): p. 102-108.
Rumsfeld, J.S., et al., Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. American Heart Journal, 2005. 150(5): p. 961-967.
Jiang, W., et al., Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Archives of internal medicine, 2001. 161(15): p. 1849-1856.
O’Connor, C.M., et al., Antidepressant use, depression, and survival in patients with heart failure. Archives of Internal Medicine, 2008. 168(20): p. 2232-2237.
Rutledge, T., et al., Depression in heart failure: a meta- analytic review of prevalence, intervention effects, and associations with clinical outcomes. Journal of the American college of Cardiology, 2006. 48(8): p. 1527-1537.
Jiang, W., et al., Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). The American journal of cardiology, 2011. 107(4): p. 545-551.
Serebruany, V.L., et al., Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation, 2003. 108(8): p. 939-944.
Page, M.J., et al., Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. Journal of clinical epidemiology, 2021. 134: p. 103-112.
Amir-Behghadami, M., SPIDER as a framework to formulate eligibility criteria in qualitative systematic reviews. BMJ Supportive & Palliative Care, 2021.
Wells, G.A., et al., The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2000, Oxford.
Mawanda, F., et al., PTSD, psychotropic medication use, and the risk of dementia among US veterans: a retrospective cohort study. Journal of the American Geriatrics Society, 2017. 65(5): p. 1043-1050.
Heath, L., et al., Cumulative antidepressant use and risk of dementia in a prospective cohort study. Journal of the American Geriatrics Society, 2018. 66(10): p. 1948-1955.
Chan, J.Y., et al., Depression and antidepressants as potential risk factors in dementia: a systematic review and meta-analysis of 18 longitudinal studies. Journal of the American Medical Directors Association, 2019. 20(3): p. 279-286. e1.
Richardson, K., et al., Anticholinergic drugs and risk of dementia: case-control study. bmj, 2018. 361.
Almeida, O., et al., Depression as a modifiable factor to decrease the risk of dementia. Translational psychiatry, 2017. 7(5): p. e1117-e1117.
Xie, Y., et al., The effect of selective serotonin reuptake inhibitors on cognitive function in patients with Alzheimer’s disease and vascular dementia: focusing on fluoxetine with long follow-up periods. Signal transduction and targeted therapy, 2019. 4(1): p. 1-3.
Guo, M., et al., Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clinical and experimental pharmacology and physiology, 2014. 41(9): p. 650-656.
Tsai, L.-H. and J.-W. Lin. A case report on elderly psychotic-like symptoms caused by antidepressant discontinuation. in Annales Médico-psychologiques, revue psychiatrique. 2021. Elsevier.
Giovannini, S., et al., Use of antidepressant medications among older adults in European long-term care facilities: a cross-sectional analysis from the SHELTER study. BMC geriatrics, 2020. 20(1): p. 1-10.
Knegtering, H., M. Eijck, and A. Huijsman, Effects of antidepressants on cognitive functioning of elderly patients. Drugs & aging, 1994. 5(3): p. 192-199.
Leng, Y., et al., Antidepressant use and cognitive outcomes in very old women. The Journals of Gerontology: Series A, 2018. 73(10): p. 1390-1395.
Diez-Quevedo, C., et al., Depression, antidepressants, and long-term mortality in heart failure. International Journal of Cardiology, 2013. 167(4): p. 1217-1225.
Woroń, J., M. Siwek, and A. Gorostowicz, Adverse effects of interactions between antidepressants and medications used in treatment of cardiovascular disorders. Psychiatr Pol, 2019. 53(5): p. 977-995.
Biffi, A., et al., Antidepressants and the risk of cardiovascular events in elderly affected by cardiovascular disease: a real-life investigation from Italy. Journal of Clinical Psychopharmacology, 2020. 40(2): p. 112-121.
Kahl, K.G., Direct and indirect effects of psychopharmacological treatment on the cardiovascular system. Hormone molecular biology and clinical investigation, 2018. 36(1).
Carrière, I., et al., Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Archives of internal medicine, 2009. 169(14): p. 1317-1324.

Еще

Статья научная